A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Repeated Subcutaneously Administered RBD4059 in Participants with Stable Coronary Artery Disease
Active, not recruitingCTIS2023-510370-14-00
Ribocure Pharmaceuticals ABStable Coronary Artery Disease
Start: 2024-08-28Target: 30Updated: 2025-12-12